Stem Cell Assay Global Market Report 2024

Stem cells are cells possessing the unique ability to self-renew and differentiate into specialized cell types, serving as the foundational elements for all living organisms. Stem cell assays are specifically designed to explore the growth of human stem cells and examine their biological activities within a controlled environment.

The primary categories within the stem cell assays market include cell viability and toxicity assays, cell apoptosis assays, cell function assays, cell identification assays, isolation and purification assays, and cell differentiation assays, among others. Cell viability and toxicity assays are employed to evaluate the physical and physiological health of cells under various conditions, such as exposure to external stimuli, chemical agents, medicinal treatments, or other factors, aiding in the determination of optimal conditions for cell culture growth. Products associated with these assays include instruments and detection kits utilized in diverse applications like regenerative medicine, therapy development, drug discovery, and clinical research. End users span government research institutes, private research institutes, and industry research.

The stem cell assay market research report is one of a series of new reports that provides stem cell assay market statistics, including stem cell assay industry global market size, regional shares, competitors with an stem cell assay market share, detailed stem cell assay market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell assay industry. This stem cell assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stem cell assay market size has grown exponentially in recent years. It will grow from $1.94 billion in 2023 to $2.35 billion in 2024 at a compound annual growth rate (CAGR) of 21.2%. The expansion witnessed in the historical period can be ascribed to advancements in biotechnology, progress in drug discovery and development, research in regenerative medicine, the modeling of diseases, and substantial investments from both public and private sectors.

The stem cell assay market size is expected to see exponential growth in the next few years. It will grow to $5.16 billion in 2028 at a compound annual growth rate (CAGR) of 21.7%. The anticipated growth in the forecast period is linked to the development of personalized medicine and cell therapy, advancements in organoid and tissue engineering, the integration of AI and machine learning, the emergence of new technologies, and increased attention to regulatory and ethical considerations. Major trends expected in the forecast period encompass the adoption of 3D cell culture models, the use of high-throughput screening, the expansion of personalized medicine, the application of CRISPR-Cas9 and genome editing, and the focus on drug safety and toxicity testing.

The anticipated increase in the prevalence of chronic diseases is expected to drive the growth of the stem cell assay market in the future. Chronic diseases, lasting three months or longer with the potential to worsen over time, can be addressed using stem cells, which have the capability to treat various ailments, including chronic conditions like cancer. For instance, data from the Australian Bureau of Statistics in 2021 revealed that nearly 46.6% of Australians of all ages had one or more chronic diseases, and 20.7% had two or more chronic diseases. Consequently, the rising incidence of chronic diseases is a significant factor fueling the expansion of the stem cell assay market.

The expanding healthcare sector is also expected to be a driving force behind the growth of the stem cell assay market. The healthcare sector, comprising organizations, professionals, and resources dedicated to providing medical services and products, utilizes stem cell assays for drug discovery, toxicity testing, disease modeling, and understanding developmental biology. In 2021, the global healthcare sector demonstrated growth, returning +19.8%, according to BlackRock Inc., a US-based investment management corporation. Thus, the increasing demand within the healthcare sector is poised to continue propelling the growth of the stem cell assay market in the forecast period.

A key trend gaining traction in the stem cell assay market is product innovation. Major companies in this market are introducing new products to maintain their competitive positions. For example, in May 2022, Beckman Coulter Life Sciences, a US-based healthcare company, introduced the AQUOS STEM System designed to aid in the development of hematopoietic stem cells. This system reduces hands-on time by 95%, minimizes error-prone processes by 87.5%, and shortens turnaround times, running on the AQUIOS CL Flow Cytometer that combines sample preparation and analysis in a compact platform.

Innovative technologies such as the LIVE Cell Death Assay (LCDA) are being developed by major companies in the stem cell assay market to meet the growing demand. LCDA, an automated solution for profiling cell health, death, apoptosis, and necrosis, offers 13 viability and death-related metrics. For instance, in September 2022, Nanolive SA, a Switzerland-based biotechnology company, launched LCDA, which finds applications in drug discovery, enabling the analysis of cell conditions related to health, stress, cell death, and recovery. This method employs machine learning to automatically measure and track cell well-being and the progression of cell death while distinguishing between apoptosis and necrosis.

In July 2022, Fujifilm Cellular Dynamics Inc., a US-based manufacturer of human-induced pluripotent stem cell technologies, entered into a partnership with PhenoVista Biosciences. This collaboration aims to provide drug discovery researchers with services for high content screening imaging using iPSC-derived differentiated cells, contributing to the drug discovery process. PhenoVista Biosciences, a US-based company, specializes in offering imaging-based phenotypic assay services for drug discovery using induced pluripotent stem cells (iPSCs) in screening.

Major companies operating in the stem cell assay market include Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories Inc., PerkinElmer Inc., Agilent Technologies Inc., Promega Corporation, Cell Biolabs Inc., Miltenyi Biotec GmbH, STEMCELL Technologies Inc., Bio-Techne Corporation, Charles River Laboratories International Inc., Hemogenix Inc., Lonza Group AG, Takara Bio Inc., Creative Bioarray, AAT Bioquest Inc., BPS Bioscience Inc., Enzo Life Sciences Inc., PromoCell GmbH, Biotium Inc., Geno Technology Inc., Abcam PLC, ReachBio Research Labs. Inc., Sartorius AG, Eppendorf AG, Corning Incorporated, Smith & Nephew PLC, MEDIPOST Co. Ltd., Anterogen Co. Ltd., Corestemchemon Inc., Pharmicell Inc., NuVasive Inc., RTI Surgical Holdings Inc., AlloSource LifeSource Services Inc., JCR Pharmaceuticals Co. Ltd.

North America was the largest region in the stem cell assay market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the global stem cell assay industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the stem cell assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The stem cell assay market consists of sales of tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, proliferation assays, differentiation assays, function assays, caspase assays and annexin v and cell permeability assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.